Parametric Portfolio Associates’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Parametric Portfolio Associates’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$74K	Buy	+920	New	+$114K	﹤0.01%	3599

Other funds holding VINC

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parametric Portfolio Associates's VINC Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2022: 920 shares worth $74K. The stake represents ﹤0.01% of the portfolio and ranks #3599 among its holdings.

68 funds tracked by Wall St. Rank hold VINC as of Q1 2022.

Parametric Portfolio Associates held 920 shares of Vincerx Pharma, Inc. Common Stock worth $74K as of Q1 2022.
Vincerx Pharma, Inc. Common Stock was a new Parametric Portfolio Associates position in Q1 2022.
Vincerx Pharma, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3599 holding.
68 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.